Radium(223) Dichloride (Alpharadin) in Castration-Resistant (Hormone-Refractory) Prostate Cancer Patients With Bone Metastases
This study is a prospective, interventional, open-label, multi-center early access program for the use of Ra-223 Cl2 in HRPC/CRPC (Hormone refractory prostate cancer / Castrate resistant prostate cancer) patients diagnosed with bone metastasis and to collect additional short and long term safety data on the product.
Prostatic Neoplasms
DRUG: Radium-223 dichloride (BAY88-8223)
Acute safety, variables will be summarized using descriptive statistics based on adverse events collection, Safety variables to be analyzed during the treatment period include: ECOG PS, Skeletal-related events, Treatment emergent Grade 3-4 AEs, any grade of treatment-related AEs and SAEs, Safety laboratory tests including hematology and serum chemistry, From baseline to 30 days post-treatment|Long-term safety, variables will be summarized using descriptive statistics based on adverse events collection, Safety variables to be analyzed during the follow-up period include: Skeletal-related events, Treatment related AEs and SAEs, Secondary malignancies, From 30 days post-treatment up to 3 years
Brief Pain Inventory, as assessed by BPI-SF questionnaire (Brief Pain Inventory-Short Form), From baseline up to 1 year
This study is a prospective, interventional, open-label, multi-center early access program for the use of Ra-223 Cl2 in HRPC/CRPC (Hormone refractory prostate cancer / Castrate resistant prostate cancer) patients diagnosed with bone metastasis and to collect additional short and long term safety data on the product.